177 related articles for article (PubMed ID: 25889691)
1. Analytical platform evaluation for quantification of ERG in prostate cancer using protein and mRNA detection methods.
He J; Schepmoes AA; Shi T; Wu C; Fillmore TL; Gao Y; Smith RD; Qian WJ; Rodland KD; Liu T; Camp DG; Rastogi A; Tan SH; Yan W; Mohamed AA; Huang W; Banerjee S; Kagan J; Srivastava S; McLeod DG; Srivastava S; Petrovics G; Dobi A; Srinivasan A
J Transl Med; 2015 Feb; 13():54. PubMed ID: 25889691
[TBL] [Abstract][Full Text] [Related]
2. Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.
He J; Sun X; Shi T; Schepmoes AA; Fillmore TL; Petyuk VA; Xie F; Zhao R; Gritsenko MA; Yang F; Kitabayashi N; Chae SS; Rubin MA; Siddiqui J; Wei JT; Chinnaiyan AM; Qian WJ; Smith RD; Kagan J; Srivastava S; Rodland KD; Liu T; Camp DG
Mol Oncol; 2014 Oct; 8(7):1169-80. PubMed ID: 25266362
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer marker panel with single cell sensitivity in urine.
Nickens KP; Ali A; Scoggin T; Tan SH; Ravindranath L; McLeod DG; Dobi A; Tacha D; Sesterhenn IA; Srivastava S; Petrovics G
Prostate; 2015 Jun; 75(9):969-75. PubMed ID: 25808739
[TBL] [Abstract][Full Text] [Related]
4. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
[TBL] [Abstract][Full Text] [Related]
5. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
Cornu JN; Cancel-Tassin G; Egrot C; Gaffory C; Haab F; Cussenot O
Prostate; 2013 Feb; 73(3):242-9. PubMed ID: 22821767
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.
Rice KR; Chen Y; Ali A; Whitman EJ; Blase A; Ibrahim M; Elsamanoudi S; Brassell S; Furusato B; Stingle N; Sesterhenn IA; Petrovics G; Miick S; Rittenhouse H; Groskopf J; McLeod DG; Srivastava S
Clin Cancer Res; 2010 Mar; 16(5):1572-6. PubMed ID: 20160063
[TBL] [Abstract][Full Text] [Related]
7. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
8. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
Salami SS; Schmidt F; Laxman B; Regan MM; Rickman DS; Scherr D; Bueti G; Siddiqui J; Tomlins SA; Wei JT; Chinnaiyan AM; Rubin MA; Sanda MG
Urol Oncol; 2013 Jul; 31(5):566-71. PubMed ID: 21600800
[TBL] [Abstract][Full Text] [Related]
9. Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics.
Wang H; Barbieri CE; He J; Gao Y; Shi T; Wu C; Schepmoes AA; Fillmore TL; Chae SS; Huang D; Mosquera JM; Qian WJ; Smith RD; Srivastava S; Kagan J; Camp DG; Rodland KD; Rubin MA; Liu T
J Transl Med; 2017 Aug; 15(1):175. PubMed ID: 28810879
[TBL] [Abstract][Full Text] [Related]
10. Delineation of TMPRSS2-ERG splice variants in prostate cancer.
Hu Y; Dobi A; Sreenath T; Cook C; Tadase AY; Ravindranath L; Cullen J; Furusato B; Chen Y; Thangapazham RL; Mohamed A; Sun C; Sesterhenn IA; McLeod DG; Petrovics G; Srivastava S
Clin Cancer Res; 2008 Aug; 14(15):4719-25. PubMed ID: 18676740
[TBL] [Abstract][Full Text] [Related]
11. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer.
Laxman B; Morris DS; Yu J; Siddiqui J; Cao J; Mehra R; Lonigro RJ; Tsodikov A; Wei JT; Tomlins SA; Chinnaiyan AM
Cancer Res; 2008 Feb; 68(3):645-9. PubMed ID: 18245462
[TBL] [Abstract][Full Text] [Related]
12. Study of genetic and epigenetic alterations in urine samples as diagnostic markers for prostate cancer.
Dimitriadis E; Kalogeropoulos T; Velaeti S; Sotiriou S; Vassiliou E; Fasoulis L; Klapsas V; Synesiou M; Apostolaki A; Trangas T; Pandis N
Anticancer Res; 2013 Jan; 33(1):191-7. PubMed ID: 23267145
[TBL] [Abstract][Full Text] [Related]
13. Detection of TMPRSS2-ERG fusion transcripts and prostate cancer antigen 3 in urinary sediments may improve diagnosis of prostate cancer.
Hessels D; Smit FP; Verhaegh GW; Witjes JA; Cornel EB; Schalken JA
Clin Cancer Res; 2007 Sep; 13(17):5103-8. PubMed ID: 17785564
[TBL] [Abstract][Full Text] [Related]
14. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion.
Washington MN; Weigel NL
Endocrinology; 2010 Apr; 151(4):1409-17. PubMed ID: 20147525
[TBL] [Abstract][Full Text] [Related]
15. YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion.
Rahim S; Beauchamp EM; Kong Y; Brown ML; Toretsky JA; Üren A
PLoS One; 2011 Apr; 6(4):e19343. PubMed ID: 21559405
[TBL] [Abstract][Full Text] [Related]
16. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers.
Mani RS; Iyer MK; Cao Q; Brenner JC; Wang L; Ghosh A; Cao X; Lonigro RJ; Tomlins SA; Varambally S; Chinnaiyan AM
Cancer Res; 2011 Aug; 71(16):5387-92. PubMed ID: 21676887
[TBL] [Abstract][Full Text] [Related]
17. Immunocytochemical detection of ERG expression in exfoliated urinary cells identifies with high specificity patients with prostate cancer.
Pal RP; Kockelbergh RC; Pringle JH; Cresswell L; Hew R; Dormer JP; Cooper C; Mellon JK; Barwell JG; Hollox EJ
BJU Int; 2016 Apr; 117(4):686-96. PubMed ID: 26471473
[TBL] [Abstract][Full Text] [Related]
18. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
Miyagi Y; Sasaki T; Fujinami K; Sano J; Senga Y; Miura T; Kameda Y; Sakuma Y; Nakamura Y; Harada M; Tsuchiya E
Mod Pathol; 2010 Nov; 23(11):1492-8. PubMed ID: 20693979
[TBL] [Abstract][Full Text] [Related]
19. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer.
Wu L; Zhao JC; Kim J; Jin HJ; Wang CY; Yu J
Cancer Res; 2013 Oct; 73(19):6068-79. PubMed ID: 23913826
[TBL] [Abstract][Full Text] [Related]
20. A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer.
Qu X; Randhawa G; Friedman C; O'Hara-Larrivee S; Kroeger K; Dumpit R; True L; Vakar-Lopez F; Porter C; Vessella R; Nelson P; Fang M
Cancer Genet; 2013; 206(1-2):1-11. PubMed ID: 23352841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
